<?xml version="1.0" encoding="UTF-8"?>
<p>To date, there are no licensed vaccines or therapeutics for prevention or treatment of MERS-CoV infection and therapy is focused on supportive care to relive symptoms and in more severe cases to also support function of vital organs (
 <xref rid="ref100" ref-type="bibr">Modjarrad, 2016</xref>; 
 <xref rid="ref104" ref-type="bibr">Mustafa et al., 2018</xref>). Since no specific treatment is available, supportive therapy and the use of broad-spectrum antivirals are currently the options for treatment (
 <xref rid="ref119" ref-type="bibr">Rabaan et al., 2017</xref>). A broad range of therapeutics have been used in the clinic to treat MERS-CoV-infected patients, and their use is based on knowledge obtained during the severe acute respiratory syndrome (SARS) outbreak in 2003 and the recent influenza pandemic in 2009 (
 <xref rid="ref99" ref-type="bibr">Mo and Fisher, 2016</xref>). Furthermore, comprehensive clinical studies are lacking and only field data are available (
 <xref rid="ref44" ref-type="bibr">Dyall et al., 2017</xref>).
</p>
